Comparative Pharmacology
Head-to-head clinical analysis: KEVZARA versus LEMTRADA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KEVZARA versus LEMTRADA.
KEVZARA vs LEMTRADA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Interleukin-6 (IL-6) receptor antagonist; sarilumab binds specifically to both soluble and membrane-bound IL-6 receptors, inhibiting IL-6-mediated signaling through gp130 and STAT3.
Alemtuzumab is a humanized monoclonal antibody that binds to CD52, a protein expressed on the surface of mature lymphocytes (T and B cells) and to a lesser extent on monocytes, macrophages, and NK cells. Binding to CD52 induces antibody-dependent cell-mediated cytolysis and complement-mediated lysis, resulting in prolonged depletion of circulating lymphocytes.
200 mg subcutaneously once weekly.
12 mg/day intravenously over 4 hours on 5 consecutive days (total 60 mg), followed by 12 mg/day intravenously over 4 hours on 3 consecutive days (total 36 mg) 12 months later.
None Documented
None Documented
Terminal elimination half-life ~21-22 days, supporting subcutaneous dosing every 2 weeks.
12.7 days (range 7.7–22.1 days) after multiple doses; clinically relevant for prolonged lymphocyte depletion.
Primarily eliminated via reticuloendothelial system catabolism. No significant renal or biliary excretion; <1% excreted unchanged in urine or feces.
Renal (primarily via catabolism to peptides and amino acids, minimal intact drug in urine). No specific biliary or fecal elimination data.
Category C
Category C
Monoclonal Antibody, IL-6 Receptor Antagonist
Monoclonal Antibody